Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.

By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose (MTD) level of 0.5 mg/day. This means that a step-wise intra-patient dose-escalation enables a dose of 1 mg/day to be administered in future clinical trials.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Sven Andréasson, President and CEO of Active Biotech.

The ongoing 10-week study comprises patients with so called hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.

PSA measurements were recorded and PSA velocity (PSAV) was calculated after 28 days of treatment. Five out of six patients had a >50% decrease in PSA velocity compared to prior treatment. Three of these five patients exhibited a decrease in absolute PSA levels.

The study is being performed at the urological clinics at the University Hospitals in Lund, Malmö and Uppsala, Sweden.

The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved on the new MTD to be used in the continued clinical program of TASQ.

The pharmaceutical market for prostate cancer is estimated at more than USD 3 billion a year. Prostat e cancer is the most common form of cancer among men. The incidence is strongly age-related and is unusual before age 50. In 2006, 2.2 million new cases were estimated to have been diagnosed in the US alone.

Lund, March 9, 2007

Active Biotech AB (publ) Sven Andréasson President and CEO

For further information, please contact: Sven Andréasson, President and CEO, tel. +46 46 19 20 49 Tomas Leanderson, Chief Scientific Officer, tel +46 46 19 20 95 Cecilia Hofvander, Manager Corporate Communication, tel. +46 46 19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org.nr 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Research and Markets has announced ... Opportunities, and Future" report to their offering. ... This research service on the ... technologies, and provides a snapshot of the key participants in the ... are provided from 2016 to 2020. The market is expected to ...
(Date:1/20/2017)... -- Avillion LLP, a co-developer and financier of late-stage ... MD MBA as Chief Medical Officer. Dr Weinberg will be based ... ... spent more than 17 years as a pharmaceutical and biotech executive ... Over the course of his career, he has interfaced with the ...
(Date:1/19/2017)... , Jan. 19, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women ... of recovery, they often feel shame for having struggled with an eating disorder as ... the workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, Inc. ... or need, from clothes to couches to dressers and bicycles. Roadie — the national ... the nearest Goodwill donation center through February 28th. , “January is an exciting ...
(Date:1/20/2017)... ... ... Doctor C LLC, a company based out of Arizona that focuses on ... marketing and distribution of its product, The Right C. , The Right C is ... traditional vitamin C supplements. At the trade show, Doctor C had the opportunity to ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K ... 4K Mystique lens flare and light leak transitions have a very high-dynamic range for ...
Breaking Medicine News(10 mins):